Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|August 14, 2025
Oral Peanut Immunotherapy With Butyrate Adjuvant (OPIA) in Children: A Randomised, Controlled TrialPeter S Hsu, Elizabeth H Barnes, Michelle Barnes, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 12, 2015
Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosisSudarshini Ramanathan, Kristina Prelog, Elizabeth H Barnes, et al.
JCI Insight|September 7, 2018
Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary preventionPiyushkumar A Mundra, Christopher K Barlow, Paul J Nestel, et al.
Circulation|October 21, 2016
Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes MellitusZahir H Alshehry, Piyushkumar A Mundra, Christopher K Barlow, et al.
JCI Insight|July 12, 2019
Changes in plasma lipids predict pravastatin efficacy in secondary preventionKaushala S Jayawardana, Piyushkumar A Mundra, Corey Giles, et al.
BMJ Open|May 15, 2023
LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot studyBenjamin Y Kong, Hao-Wen Sim, Anna K Nowak, et al.
BMJ Open|August 4, 2023
[18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
The Lancet. Oncology|April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trialLinda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.
Neuro-Oncology Advances|October 16, 2023
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastomaHao-Wen Sim, Luke Wachsmuth, Elizabeth H Barnes, et al.
Pageof 7